News

cardiologists heart doctors

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

heart drugs with stethoscope

An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.

Cerepak Detachable Coil Systems

Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

the words "FDA recall" on a board

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

heart surgery surgeons

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

Cardiac surgeon and innovator Thomas Fogerty, MD, who was awarded the Presidential Medal of Technology.

Fogarty created many inventions that fundamentally changed cardiac surgical practice. He also received the Presidential Medal of Technology and Innovation from President Barack Obama in 2014.

doctorwithpatient.jpg

Improvements in care have resulted in a growing number of patients who go on to be diagnosed with both cancer and severe aortic stenosis. TAVR appears to be an effective treatment option for those individuals, and it may help them go on to receive life-saving cancer therapies.

Nick West, MD, chief medical officer, Shockwave Medical, Johnson and Johnson Meditech, explains how the company is innovating intravascular lithotripsy (IVL) therapy devices and building clinical evidence from trials for its use in a variety of calcified lesions. There are several companies developing IVL therapy, but West says Shockwave will remain the market leader because of its nearly decade long head start in the market, strong clinical evidence and has about a 10% market penetration. #IVKL

Nick West, MD, Shockwave Medical's chief medical officer, detailed how the company is continuing to push IVL technologies forward. "We are leading the space ... we have no intention of giving up that position," he said.

the words "FDA recall" on a board

This is a Class I recall, which means the FDA believes these devices could cause a serious injury or death.

Around the web

Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's  FDA 510(k)-pending photon-counting CT scanner.